Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Phase II Trial to Evaluate the Safety and Efficacy of Neoadjuvant Radiotherapy Combined With Immunotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma

NCT05861557 is registered in ClinicalTrials.gov with Tianjin Medical University General Hospital as lead sponsor.

NCT NCT05861557
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05861557 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Phase II Trial to Evaluate the Safety and Efficacy of Neoadjuvant Radiotherapy Combined With Immunotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma
Lead sponsor
Tianjin Medical University General Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
May 20, 2023
Completion date
May 20, 2025
Enrollment
23 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced head and neck squamous cell carcinoma